- Home
- RMAX vs GNLX Comparison
RMAX vs GNLX Comparison
Compare RMAX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- GNLX
- Stock Information
- Founded
- RMAX 1973
- GNLX 2001
- Country
- RMAX United States
- GNLX United States
- Employees
- RMAX N/A
- GNLX N/A
- Industry
- RMAX Real Estate
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- GNLX Health Care
- Exchange
- RMAX Nasdaq
- GNLX Nasdaq
- Market Cap
- RMAX 161.9M
- GNLX 184.4M
- IPO Year
- RMAX 2013
- GNLX 2023
- Fundamental
- Price
- RMAX $8.70
- GNLX $3.40
- Analyst Decision
- RMAX Sell
- GNLX Strong Buy
- Analyst Count
- RMAX 2
- GNLX 4
- Target Price
- RMAX $8.75
- GNLX $18.25
- AVG Volume (30 Days)
- RMAX 177.3K
- GNLX 172.9K
- Earning Date
- RMAX 05-01-2025
- GNLX 03-31-2025
- Dividend Yield
- RMAX N/A
- GNLX N/A
- EPS Growth
- RMAX N/A
- GNLX N/A
- EPS
- RMAX 0.37
- GNLX N/A
- Revenue
- RMAX $307,685,000.00
- GNLX $8,000.00
- Revenue This Year
- RMAX N/A
- GNLX N/A
- Revenue Next Year
- RMAX $1.25
- GNLX N/A
- P/E Ratio
- RMAX $23.51
- GNLX N/A
- Revenue Growth
- RMAX N/A
- GNLX N/A
- 52 Week Low
- RMAX $6.94
- GNLX $1.60
- 52 Week High
- RMAX $14.31
- GNLX $6.50
- Technical
- Relative Strength Index (RSI)
- RMAX 41.50
- GNLX 40.17
- Support Level
- RMAX $8.25
- GNLX $3.51
- Resistance Level
- RMAX $8.77
- GNLX $3.90
- Average True Range (ATR)
- RMAX 0.40
- GNLX 0.44
- MACD
- RMAX -0.00
- GNLX -0.13
- Stochastic Oscillator
- RMAX 40.60
- GNLX 9.43
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.